Madrigal Pharmaceuticals
Madrigal is a biopharmaceutical company focused on developing therapeutics for metabolic liver disease. They are emphasizing a culture of scientific excellence, operational rigor, and collaboration, with ongoing clinical trials for their medication Rezdiffra.
Headquarters
Conshohocken, Pennsylvania, United States
Company Size
201-500 employees
Founded
2016
Delivering a Breakthrough Treatment Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse […]
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2 weeks ago
Senior Manager/Associate Director, Business Development
Kura Oncology
Director, Patient Advocacy
Zevra
Lead Product Designer
Click Therapeutics
KAM Rare Diseases (Valladolid)
Ipsen
CVRM Global Medical Digital Strategy & Innovation Director
AstraZeneca
Associate Scientist, In Vivo & In Vitro
Regeneron Pharmaceuticals